Evidence map›Paper›PMID 33687470›Full record

GuidelineJAMA2021

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force, Alex H Krist, Karina W Davidson, Carol M Mangione, Michael J Barry, Michael Cabana, Aaron B Caughey, Esa M Davis, Katrina E Donahue, Chyke A Doubeni and 10 more

7 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 983 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
983citing papers in PubMed, 3 pooled it
168.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04974632 nacompletednot on this map

Mobile 3D C-arm CT for Lung Tumor Localization Efficacy Analysis: a Prospective Clinical Trial

TypeinterventionalSponsorChang Gung Memorial HospitalRan2021 to 2022Enrolled41ConditionsLung Tumor, Thoracoscopic SurgeryArmslocalization
NCT05227261 completednot on this mapstarted 2022, after this paper: background citation

Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA

TypeobservationalSponsorGene SolutionsRan2022 to 2024Enrolled9,057ConditionsCancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
NCT05557487 recruitingnot on this mapstarted 2022, after this paper: background citation

Taiwan Real-world Low-dose Computed Tomography Screening behavIor and Outcome Research for High Risk Subjects Based on Health Promotion Administration-part A: Questionnaire Survey -Part B: LDCT Screening Outcome and Management

TypeobservationalSponsorGee-Chen ChangRan2022 to 2028Enrolled6,618ConditionsLung Cancer, High-Risk Cancer, Smoking, PollutionArmsLow dose computed tomography
NCT05738031 withdrawnnot on this mapstarted 2023, after this paper: background citation

Investigating Incidental Pulmonary Nodules in Underserved Communities

TypeobservationalSponsorMontefiore Medical CenterRan2023 to 2025Enrolled0ConditionsLung, Node
NCT06473870 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Understanding Lung Cancer Related Risk Factors and Their Impact

Typeobservational_patient_registrySponsorBiobizkaia Health Research InstituteRan2024 to 2027Enrolled6,160ConditionsLung Cancer Screening
NCT07126626 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer

TypeobservationalSponsorGene SolutionsRan2025 to 2027Enrolled1,184ConditionsLung Diseases, Lung Cancer Screening
NCT07572773 narecruitingnot on this mapstarted 2026, after this paper: background citation

CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program

TypeinterventionalSponsorJill KolesarRan2026 to 2028Enrolled300ConditionsLung Cancer, Early Lung Cancer DetectionArmsDELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan
3 · Its place in the literature

Who cites it

983 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,627 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Associations between Metabolomic Signatures of Persistent Smoking Effects and Lung Cancer Risk among Former Smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  19. Review
  20. Article

923 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 1 country.

US Preventive Services Task Force
Alex H KristFairfax Family Practice Residency, Fairfax, Virginia.
Karina W DavidsonFeinstein Institute for Medical Research at Northwell Health, Manhasset, New York.
Carol M MangioneUniversity of California, Los Angeles.
Michael J BarryHarvard Medical School, Boston, Massachusetts.
Michael CabanaUniversity of California, San Francisco.
Aaron B CaugheyOregon Health & Science University, Portland.
Esa M DavisUniversity of Pittsburgh, Pittsburgh.
Katrina E DonahueUniversity of North Carolina at Chapel Hill.
Chyke A DoubeniMayo Clinic, Rochester, Minnesota.
Martha KubikGeorge Mason University, Fairfax, Virginia.
C Seth LandefeldUniversity of Alabama at Birmingham.
Li LiUniversity of Virginia, Charlottesville.
Gbenga OgedegbeNew York University, New York.
Douglas K OwensStanford University, Stanford, California.
Lori PbertUniversity of Massachusetts Medical School, Worcester.
Michael SilversteinBoston University, Boston, Massachusetts.
James StevermerUniversity of Missouri, Columbia.
Chien-Wen TsengUniversity of Hawaii, Honolulu.
John B WongTufts University School of Medicine, Boston, Massachusetts.
Harvard University · USNorthwell Health · USOregon Health & Science University · USUniversity of Hawaiʻi at Mānoa · USUniversity of Massachusetts Chan Medical School · USUniversity of North Carolina at Chapel Hill · USGeorge Mason University · USMayo Clinic · USNew York University · USTufts University · USUniversity of Alabama at Birmingham · USUniversity of Missouri · USUniversity of Virginia · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceLung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung cancer. Lung cancer has a generally poor prognosis, with an overall 5-year survival rate of 20.5%. However, early-stage lung cancer has a better prognosis and is more amenable to treatment.

objectiveTo update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the accuracy of screening for lung cancer with low-dose computed tomography (LDCT) and on the benefits and harms of screening for lung cancer and commissioned a collaborative modeling study to provide information about the optimum age at which to begin and end screening, the optimal screening interval, and the relative benefits and harms of different screening strategies compared with modified versions of multivariate risk prediction models. POPULATION: This recommendation statement applies to adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that annual screening for lung cancer with LDCT has a moderate net benefit in persons at high risk of lung cancer based on age, total cumulative exposure to tobacco smoke, and years since quitting smoking. RECOMMENDATION: The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation) This recommendation replaces the 2013 USPSTF statement that recommended annual screening for lung cancer with LDCT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.

Indexed as

Early Detection of CancerSmokingTomography, X-Ray ComputedAgedAged, 80 and overHumansLungLung NeoplasmsMiddle AgedRisk AssessmentSensitivity and SpecificitySmoking Cessation

Identifiers

PMID33687470
OpenAlexW3134934271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.